Acurx Pharmaceuticals (Acurx Pharmaceuticals) EBIT per Share : $-1.18 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals EBIT per Share?

Acurx Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2024 was $-0.28. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.18.

During the past 3 years, the average EBIT per Share Growth Rate was -33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Acurx Pharmaceuticals's EBIT per Share or its related term are showing as below:

ACXP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -33.6 Med: -22.9 Max: -12.2
Current: -33.6

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Acurx Pharmaceuticals was -12.20% per year. The lowest was -33.60% per year. And the median was -22.90% per year.

ACXP's 3-Year EBIT Growth Rate is ranked worse than
84.65% of 1303 companies
in the Biotechnology industry
Industry Median: 3.6 vs ACXP: -33.60

Acurx Pharmaceuticals's EBIT for the three months ended in Mar. 2024 was $-4.38 Mil.

Acurx Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Acurx Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals EBIT per Share Chart

Acurx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.79

-0.48

-1.50

-1.12

-1.15

Acurx Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.25	-0.28	-0.24	-0.37	-0.28

Acurx Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Acurx Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.578	/	12.672
=	-1.15

Acurx Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.378	/	15.473
=	-0.28

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.18

Acurx Pharmaceuticals (NAS:ACXP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Acurx Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

3ZO:Germany

Address

259 Liberty Avenue, Staten Island, NY, USA, 10305

Website

https://www.acurxpharma.com

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Executives

David P Luci	director, 10 percent owner, officer: President and CEO
Robert J Deluccia	director, 10 percent owner	40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer	director	4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison	director
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean	director	C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah	officer: Chief Financial Officer	C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue	director	C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305